KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously entered a definitive agreement to acquire 180 Life Sciences, a clinical-stage biotechnology company, recently announced the appointment of Professor Richard Barker, Larry Gold Md., Shoshana Shendelman PhD., and Donald McGovern … Continue reading “QualityStocksNewsBreaks – 180 Life Sciences Corp. Announces New Board Appointments”
180 Life Sciences, a clinical-stage biotechnology company, is focused on research to solve one of the world’s most significant drivers of disease – inflammation. The company currently has three programs for the development of novel drugs in the areas of fibrosis and anti-TNF, inflammatory pain and ulcerative colitis in ex-smokers. A recent article discusses the … Continue reading “QualityStocksNewsBreaks – 180 Life Sciences Corp. Setting the Stage for Success in Bringing Novel Products to Market”
180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to … Continue reading “QualityStocksNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials”
Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years … Continue reading “180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021”
KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate in Phase 2b/3, helping mitigate the risks involved with its drug development The merger with 180 Life Sciences will enable … Continue reading “KBL Merger Corp. IV (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp.”
180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF when … Continue reading “180 Life Sciences Corp. Pursuing Novel Solutions to Inflammatory Illnesses as Merger Nears Completion”
180 Life Sciences, a clinical-stage biotechnology company, is focused on the development of novel drugs that fulfill unmet needs for a variety of conditions including fibrosis, pain and inflammatory diseases. 180 Life Sciences will soon form a combined company with KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant … Continue reading “QualityStocksNewsBreaks – Why 180 Life Sciences Corp. Is ‘One to Watch’”
180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value The company has a large and expanding patent portfolio The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages of development … Continue reading “180 Life Sciences Corp. is “One to Watch””
Investment Considerations 180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value. The company has a large and expanding patent portfolio. The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages … Continue reading “180 Life Sciences Corp. (NASDAQ: ATNF)”
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables and specialty testing services for the worldwide life sciences and other industries, today announced its participation in the upcoming LD Micro Virtual Invitational Conference XI. The three-day, virtual investor conference will feature approximately 180 companies, presenting … Continue reading “QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) to Present at LD Micro Virtual Invitational Conference XI”
